(-1.04%) 5 062.84 points
(-1.14%) 37 948 points
(-1.24%) 15 784 points
(-1.10%) $81.72
(-2.71%) $1.975
(-2.24%) $2 305.00
(-3.71%) $26.64
(-1.51%) $947.00
(0.46%) $0.937
(1.04%) $11.10
(0.49%) $0.800
(0.15%) $93.44
Live Chart Being Loaded With Signals
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics...
Stats | |
---|---|
Šios dienos apimtis | 1.32M |
Vidutinė apimtis | 2.75M |
Rinkos kapitalizacija | 4.58B |
EPS | HKD0 ( 2023-08-23 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -19.79 |
ATR14 | HKD0.0200 (0.42%) |
Tūris Koreliacija
Alphamab Oncology Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Alphamab Oncology Koreliacija - Valiuta/Žaliavos
Alphamab Oncology Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD218.77M |
Bruto pelnas: | HKD163.54M (74.75 %) |
EPS: | HKD-0.220 |
FY | 2023 |
Pajamos: | HKD218.77M |
Bruto pelnas: | HKD163.54M (74.75 %) |
EPS: | HKD-0.220 |
FY | 2022 |
Pajamos: | HKD166.85M |
Bruto pelnas: | HKD122.64M (73.50 %) |
EPS: | HKD-0.350 |
FY | 2021 |
Pajamos: | HKD146.02M |
Bruto pelnas: | HKD142.99M (97.93 %) |
EPS: | HKD-0.444 |
Financial Reports:
No articles found.
Alphamab Oncology
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.